

Supplementary Online Content


Desai NR, Giugliano RP, Wasserman SM, et al. Association between circulating baseline proprotein convertase subtilisin kexin type 9 levels and efficacy of evolocumab. *JAMA Cardiol*. Published online January 25, 2017. doi:10.1001/jamacardio.2016.5395

eFigure 1. Distribution of Baseline PCSK9 Levels

eFigure 2. Correlation of Baseline PCSK9 Levels and Baseline LDL-C


This supplementary material has been provided by the authors to give readers additional information about their work.

eFigure 1. Distribution of Baseline PCSK9 Levels



Distribution of baseline PCSK9 levels (ng/mL) in 3016 patients from 4 phase 3 randomized, controlled trials of evolocumab as part of the Program to Reduction LDL-C and Cardiovascular Outcomes Following Inhibition of PCSK9 in Different Populations (PROFICIO).

eFigure 2. Correlation of Baseline PCSK9 Levels and Baseline LDL-C



Correlation of baseline PCSK9 levels (ng/mL) and baseline LDL-C (mg/dL) among 3016 patients from 4 phase 3 randomized, controlled trials of evolocumab as part of the Program to Reduction LDL-C and Cardiovascular Outcomes Following Inhibition of PCSK9 in Different Populations (PROFICIO). Statin-naïve patients (orange) and patients treated with statins at baseline (green).